Jupiros Gold 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed for the management of cardiovascular conditions. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the prevention of atherosclerosis. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP receptor on platelet cell membranes, further reducing platelet aggregation and thrombus formation. The combined action of these agents provides a synergistic effect in reducing the risk of cardiovascular events such as myocardial infarction, stroke, and peripheral arterial disease in patients with established atherosclerotic disease or at high risk. Jupiros Gold 20 is indicated for secondary prevention of cardiovascular events, particularly in patients requiring dual antiplatelet therapy alongside lipid-lowering treatment. It should be used under medical supervision with careful monitoring for potential adverse effects including bleeding risk, hepatic function alterations, and hypersensitivity reactions. Patient adherence to prescribed dosing and lifestyle modifications enhances therapeutic outcomes.